Jefferies Group Reiterates Buy Rating for United Drugs (UDG)
United Drugs (LON:UDG)‘s stock had its “buy” rating reiterated by analysts at Jefferies Group in a research report issued to clients and investors on Wednesday, AR Network reports. They currently have a GBX 400 ($6.25) price objective on the stock. Jefferies Group’s price target indicates a potential upside of 19.80% from the company’s current price.
A number of other firms have also recently commented on UDG. Analysts at N+1 Singer reiterated a “buy” rating on shares of United Drugs (LON:UDG) in a research note to investors on Tuesday. They now have a GBX 320 ($5.00) price target on the stock. Separately, analysts at Nplus1 Brewin reiterated a “buy” rating on shares of United Drugs (LON:UDG) in a research note to investors on Tuesday. They now have a GBX 320 ($5.00) price target on the stock. Finally, analysts at Davy Research reiterated an “outperform” rating on shares of United Drugs (LON:UDG) in a research note to investors on Friday, August 30th.
One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. United Drugs presently has a consensus rating of “Buy” and an average target price of GBX 342.50 ($5.35).
Shares of United Drugs (LON:UDG) opened at 332.30 on Wednesday. United Drugs has a one year low of GBX 208.25 and a one year high of GBX 361.80. The stock’s 50-day moving average is GBX 344.2 and its 200-day moving average is GBX 313.9. The company’s market cap is £796.7 million.
United Drug plc is a provider of services to healthcare manufacturers and pharmaceutical retailers, with operations in the United Kingdom, Ireland, the Netherlands, Belgium and the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.